Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: A retrospective, multicenter study

Gynecologic Oncology

Volumn 130, Issue 3, 2013, Pages 505-510

  Ferrandina, Gabriella ^a   Salutari, Vanda ^a   Vincenzi, Bruno ^b   Marinaccio, Marco ^c   Naglieri, Emanuele ^d   Loizzi, Vera ^e   Carpano, Silvia ^f   Amadio, Giulia ^a   Tonini, Giuseppe ^b   Scambia, Giovanni ^a   Lorusso, Domenica ^g  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^d NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f Medical Oncology   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Ovarian cancer; Salvage treatment; Trabectedin

Indexed keywords

CARBOPLATIN; DOXORUBICIN; PACLITAXEL; TRABECTEDIN;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CARDIOTOXICITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; NEUTROPENIA; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; STOMATITIS; SUDDEN DEATH; THROMBOCYTOPENIA; TRAFFIC ACCIDENT; TREATMENT REFUSAL; TREATMENT RESPONSE;

OVARIAN CANCER; SALVAGE TREATMENT; TRABECTEDIN;

ADULT; AGED; ALANINE TRANSAMINASE; ANTINEOPLASTIC AGENTS, ALKYLATING; ASPARTATE AMINOTRANSFERASES; ASTHENIA; CARCINOMA; DIOXOLES; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; NEUTROPENIA; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TETRAHYDROISOQUINOLINES;

EID: 84882449972     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.06.008     Document Type: Article

References (32)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics CA Cancer J Clin 62 1 2012 10 29
2. B.A. Goff Advanced ovarian cancer: what should be the standard of care? J Gynecol Oncol 24 1 2013 83 91
3. R.W. Naumann, and R.L. Coleman Management strategies for recurrent platinum-resistant ovarian cancer Drugs 71 11 2011 1397 1412
4. P. Harter, F. Hilpert, S. Mahner, F. Heitz, J. Pfisterer, and A. du Bois Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs Expert Rev Anticancer Ther 10 1 2010 81 88
5. N. Colombo, and M. Gore Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy Crit Rev Oncol Hematol 64 2 2007 129 138
6. Y. Takebayashi, P. Pourquier, D.B. Zimonjic, K. Nakayama, S. Emmert, and T. Ueda Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair Nat Med 7 8 2001 961 966
7. E. Erba, D. Bergamaschi, L. Bassano, G. Damia, S. Ronzoni, and G.T. Faircloth Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action Eur J Cancer 37 1 2001 97 105
8. D.G. Soares, M.S. Machado, C.J. Rocca, V. Poindessous, D. Ouaret, and A. Sarasin Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells Mol Cancer Ther 10 8 2011 1481 1489
9. M. Tavecchio, M. Simone, E. Erba, I. Chiolo, G. Liberi, and M. Foiani Role of homologous recombination in trabectedin-induced DNA damage Eur J Cancer 44 4 2008 609 618
10. M. D'Incalci, and C.M. Galmarini A review of trabectedin (ET-743): a unique mechanism of action Mol Cancer Ther 9 8 2010 2157 2163
11. P. Allavena, M. Signorelli, M. Chieppa, E. Erba, G. Bianchi, and F. Marchesi Anti-inflammatory properties of the novel antitumor agent Yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production Cancer Res 65 7 2005 2964 2971
12. G. Germano, R. Frapolli, M. Simone, M. Tavecchio, E. Erba, and S. Pesce Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells Cancer Res 70 6 2010 2235 2244
13. G. Germano, R. Frapolli, C. Belgiovine, A. Anselmo, S. Pesce, and M. Liguori Role of macrophage targeting in the antitumor activity of Trabectedin Cancer Cell 23 2013 249 262
14. B. Vincenzi, A. Napolitano, A.M. Frezza, G. Schiavon, D. Santini, and G. Tonini Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives Pharmacogenomics 11 6 2010 865 878
15. G.D. Demetri, S.P. Chawla, M. von Mehren, P. Ritch, L.H. Baker, and J.Y. Blay Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules J Clin Oncol 27 25 2009 4188 4196
16. B.J. Monk, T.J. Herzog, S.B. Kaye, C.N. Krasner, J.B. Vermorken, and F.M. Muggia Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis Eur J Cancer 48 15 2012 2361 2368
17. B.J. Monk, T.J. Herzog, S.B. Kaye, C.N. Krasner, J.B. Vermorken, and F.M. Muggia Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer J Clin Oncol 28 19 2010 3107 3114
18. C. Sessa, S. Cresta, C. Noberasco, G. Capri, E. Gallerani, and F. De Braud Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours Eur J Cancer 45 12 2009 2116 2122
19. C.N. Krasner, D.S. McMeekin, S. Chan, P.S. Braly, F.G. Renshaw, and F.M. Muggia A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens Br J Cancer 97 12 2007 1618 1624
20. 2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer Ann Oncol 20 11 2009 1794 1802
21. J.M. Del Campo, C. Sessa, C.N. Krasner, J.B. Vermorken, N. Colombo, and S. Kaye Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials Med Oncol 30 1 2013 435
22. National Cancer Institute Cancer Therapy Evaluation Program: Common Toxicity Criteria. Version 2.0 and 3.0, 1999 and 2006 http//ctep.info.nih.gov
23. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 2000 205 216
24. G.J. Rustin Use of CA-125 to assess response to new agents in ovarian cancer trials J Clin Oncol 21 Suppl. 19 2003 187 193
25. E. Kaplan, and P. Meyer Non parametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
26. N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 50 1966 163 170
27. R. Temple Hy's law: predicting serious hepatotoxicity Pharmacoepidemiol Drug Saf 15 2006 241 243
28. G. Corrado, V. Salutari, G. Fuoco, A. Lucidi, and G. Ferrandina Prolonged clinical response to trabectedin in a heavily pretreated patient with advanced uterine leiomyosarcoma: a case report and literature review Gynecol Oncol 121 2 2011 416 417
29. R. Sanfilippo, F. Grosso, R.L. Jones, S. Banerjee, S. Pilotti, and M. D'Incalci Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers Gynecol Oncol 123 3 2011 553 556
30. B.L. Samuels, S. Chawla, S. Patel, M. von Mehren, J. Hamm, and P.E. Kaiser Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study Ann Oncol Feb 5 2013
31. A. Le Cesne, A. Yovine, J.Y. Blay, S. Delaloge, R.G. Maki, and J.L. Misset A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials Invest New Drugs 30 3 2012 1193 1202
32. C. Lebedinsky, J. Gomez, Y.C. Park, A. Nieto, A. Soto-Matos, and T. Parekh Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis Cancer Chemother Pharmacol 68 2011 1223 1231